AI Startup Phylo Nabs $13.5M for Its ‘Integrated Biology Environment’

Why It Matters

By collapsing fragmented bioinformatics workflows into a single AI‑powered interface, Phylo accelerates research cycles and lowers the technical barrier for biologists, positioning the startup as a potential infrastructure layer for pharma and biotech labs.

Key Takeaways

• Phylo raised $13.5M seed round led by Andreessen Horowitz
• Biomni Lab integrates 82 tools, 68 databases, 100+ packages
• Chatbot interface lets biologists run tasks via natural language
• AI checks for hallucinations, shows script code for verification
• Free tier with limits; paid plan adds security, custom agents

Pulse Analysis

The life‑science software market has long struggled with siloed applications that require manual data reshaping and specialist bioinformatics support. Researchers often juggle multiple GUIs, command‑line tools, and proprietary formats, creating bottlenecks that delay hypothesis testing. Phylo’s Biomni Lab tackles this friction by offering an IDE‑like environment where data flows seamlessly between tools, mirroring the productivity gains seen in software development when integrated development environments became standard.

At the core of Biomni Lab is a conversational AI layer that interprets natural‑language prompts and orchestrates complex pipelines across a catalog of 82 tools and dozens of databases. The platform can dispatch heavy‑weight simulations to multi‑GPU clusters, generate 3‑D molecular visualizations, and automatically audit results for AI‑induced hallucinations, surfacing the generated script for human review. This blend of automation, scalability, and transparency not only shortens experiment turnaround—from weeks to hours in early adopters like Ginkgo Bioworks—but also democratizes advanced analytics for labs lacking dedicated computational staff.

The $13.5 million seed injection underscores investor confidence that integrated AI platforms will become foundational infrastructure for biotech. With over 4,300 organizations already testing the open‑source precursor—including 18 of the top 20 pharmaceutical firms—Phylo is poised to capture a sizable share of the emerging market for AI‑enhanced laboratory operations. Its freemium model lowers entry barriers, while the premium tier’s added cybersecurity and custom agent capabilities address enterprise compliance needs, setting the stage for recurring revenue and broader industry adoption.